The 19th JFCR-ISCC

New Antitumor Agents under Development in the US, Europe and Japan

International Symposium on Cancer Chemotherapy

ISCC

2014

December 10, (Wed)
13:00 -17:40

December 11, (Thu)
9:00 -17:35

Miraikan

National Museum of Emerging Science and Innovation
2-3-6, Aomi, Koto-ku, Tokyo, Japan

Contact:
Cancer Chemotherapy Center,
Japanese Foundation for Cancer Research
jfcr-iscc@ml.jfcr.or.jp

http://iscc.umin.jp/

Dec. 10

New Drugs and Clinical Design for Rare Types of Lung Cancers
13:10-

Jeffrey A. Engelman *MGH Cancer Center*
Resistance mechanisms to kinase inhibitors

Ryohei Katayama *Cancer Chemotherapy Center, JFCR*
New mechanisms of acquired resistance to ALK-inhibitors

Koichi Goto *National Cancer Center Hospital East*
Development of a nationwide genomic screening network and clinical trial for lung cancer with rare driver mutations

DNA Repair Pathways as Targets for Cancer Therapy
15:10 -

Yves G. Pommier *NCI, NIH*
Novel topoisomerase I inhibitors on the horizon and topoisomerase repair

Johann de Bono *Institute of Cancer Research*
Targeting PARP: What have we learnt?

Poster Session
16:40 -

Dec.11

Cancer Immuno-therapy Using Checkpoint Inhibitor Antibodies and CAR-modified T Cells
9:00 -

Koji Tamada *Yamaguchi Univ.*
Novel strategies of chimeric antigen receptor T cells for cancer immunotherapy

Jean Viallet *Bristol-Myers Squibb*
Emerging principles of combination immunotherapy for cancer: Focus on anti-CS1/SLAMF7 Elotuzumab and anti-CD137 Urelumab

Gregg Fine *Genentech inc.*
MPDL3280A: an engineered anti-PDL1 antibody specifically recognize tumor immune system and destroy tumor cells

Poster Discussion Session *11:15-*

Luncheon Seminar
12:25-

Masami Suzuki *Chugai Pharmaceutical Co., Ltd.*
Establishment of human colon cancer stem cell lines and drug discovery targeting cancer stem cells

Meet-the-Expert Seminar *13:15-*

Bruce A. Chabner *MGH Cancer Center*
Rapid approval of targeted cancer drugs: Lessons from the first decade

Targeting Epigenetics and Micro-environment for Cancer Therapy
14:25-

Kenichi Nomoto *Eisai Inc.*
Selective inhibition of EZH2 by EPZ-6438 (E7438) as personalized cancer therapy

Morihiro Watanabe *Merck Serono Ltd.*
TH-302, a hypoxia-activated prodrug with potential antineoplastic activity

New Drugs and Combination Therapy under Clinical Trials
15:25-

Keith T. Flaherty *MGH Cancer Center*
Learning from selective pressure of MAP kinase pathway inhibition in BRAF and RAS mutant cancer to develop rational combinations

Sylvie Assadourian *Sanofi S.A.*
c-Met inhibitor SAR125844

Nobuya Ishii *Chugai Pharmaceutical Co., Ltd.*
Debio1347/CH5183284: a novel selective FGFR inhibitor